clinical-stage assets – Talk Bio

Actionable Insights Powered by AI

SanegeneBio raises over $110M Series B after Lilly RNAi deal

2 days ago talkbio0Tagged clinical-stage assets, eli lilly, extrahepatic RNAi, Fund Raising, Lilly collaboration, liver-targeted RNAi, Metabolic Diseases, RNA, RNA Interference, SanegeneBio, Series B financing

SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025

Biotech IPO Market Sees Shifts in Funding and Investor Appetite

1 year ago talkbio0Tagged clinical-stage assets, Correction - Report timing, crossover, investor, IPOs, Market, venture

biotech IPOs, crossover funding, venture capital, clinical-stage assets, market correction, investor demand